longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

14:46 ET SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates ML, PWOD, NURO, CARA on Behalf of Shareholders

prnewswire
Jan 7, 2025 at 07:47 PM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Halper Sadeh LLC is investigating MoneyLion Inc. (NYSE: ML), Penns Woods Bancorp, Inc. (NASDAQ: PWOD), NeuroMetrix, Inc. (NASDAQ: NURO), and Cara Therapeutics, Inc. (NASDAQ: CARA) for potential violations of federal securities laws and breaches of fiduciary duties to shareholders. The investigations relate to proposed sales and mergers involving these companies. Halper Sadeh LLC aims to seek increased consideration for shareholders and offers legal assistance on a contingent fee basis. Shareholders are encouraged to contact the firm for more information on their rights and options.

, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

MoneyLion Inc. (NYSE: ML)'s sale to Gen Digital Inc. Under the terms of the proposed transaction, MoneyLion shareholders will receive $82.00 per share in cash, plus one contingent value right per share entitling the holder to a contingent payment in the form of shares of Gen common stock. If you are a MoneyLion shareholder, click here to learn more about your legal rights and options.

Penns Woods Bancorp, Inc. (NASDAQ: PWOD)'s sale to Northwest Bancshares, Inc. for 2.385 shares of Northwest common stock for each share of Penns Woods common stock. If you are a Penns Woods shareholder, click here to learn more about your rights and options.

NeuroMetrix, Inc. (NASDAQ: NURO)'s sale to electroCore, Inc. If you are a NeuroMetrix shareholder, click here to learn more about your legal rights and options.

Cara Therapeutics, Inc. (NASDAQ: CARA)'s merger with Tvardi Therapeutics, Inc. Upon completion of the proposed transaction, Cara shareholders are expected to own approximately 17.0% of the combined company. If you are a Cara shareholder, click here to learn more about your rights and options.

Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected].

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

Login to unlock1,906characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Related Stocks

MoneyLion

MoneyLion

USML

0.00%

NeuroMetrix

NeuroMetrix

USNURO

0.00%

Cara Therap

Cara Therap

USCARA

0.00%

LongbridgeAI